Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170. AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) ...
Tag: AbbVies
AbbVie’s Correction Appears to Be Over: Here’s Where the Stock Could Be Headed
AbbVie (ABBV) , the research-based biopharmaceutical company that was spun off from Abbott Laboratories (ABT) in 2013, has made an impressive move higher the past nine years. Recently, ABBV pulled ba...
AbbVie’s stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira
An earlier version of this report referred to Humana in the headline, not Humira. It has been corrected. Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the comp...